oxonic acid has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 3 studies
Oxonic Acid: Antagonist of urate oxidase.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Miyajima, N | 1 |
| Ragab Eissa, I | 1 |
| Abdelmoneim, M | 1 |
| Naoe, Y | 1 |
| Ichinose, T | 1 |
| Matsumura, S | 1 |
| Bustos-Villalobos, I | 1 |
| Mukoyama, N | 1 |
| Morimoto, D | 1 |
| Shibata, M | 1 |
| Takeuchi, D | 1 |
| Tsunoda, N | 1 |
| Kikumori, T | 1 |
| Tanaka, M | 1 |
| Kodera, Y | 1 |
| Kasuya, H | 1 |
| Hu, T | 1 |
| Liu, C | 1 |
| Li, Q | 1 |
| Xiong, J | 1 |
| Ma, Y | 1 |
| Wu, G | 1 |
| Zhao, Y | 1 |
| Nakayama, Y | 1 |
| Inoue, S | 1 |
| Mimura, K | 1 |
| Nakazawa, T | 1 |
| Kimura, A | 1 |
| Ohmori, M | 1 |
| Matsuda, K | 1 |
| Ichikawa, D | 1 |
3 other studies available for oxonic acid and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model.
Topics: Animals; Antimetabolites, Antineoplastic; CD8-Positive T-Lymphocytes; Drug Combinations; Fluorouraci | 2021 |
Apatinib + CPT-11 + S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer: Case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Edema; Brain Neoplasms; Camptothecin; D | 2018 |
[A Case of Triple Negative Breast Cancer Successfully Treated with S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Oxonic Acid; Tegafur; Trea | 2018 |